<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5DC4AAA7-4FB8-4B6A-9C26-71A82CF1097D"><gtr:id>5DC4AAA7-4FB8-4B6A-9C26-71A82CF1097D</gtr:id><gtr:name>Nuffield Department of Clinical Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5DC4AAA7-4FB8-4B6A-9C26-71A82CF1097D"><gtr:id>5DC4AAA7-4FB8-4B6A-9C26-71A82CF1097D</gtr:id><gtr:name>Nuffield Department of Clinical Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0C235F4A-B799-41E2-AE3E-885A84E3738E"><gtr:id>0C235F4A-B799-41E2-AE3E-885A84E3738E</gtr:id><gtr:firstName>Geoffrey</gtr:firstName><gtr:otherNames>L</gtr:otherNames><gtr:surname>Smith</gtr:surname><gtr:orcidId>0000-0002-3730-9955</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0501257"><gtr:id>6DA16932-A67D-4618-9343-D64323681B6F</gtr:id><gtr:title>Molecular pathology of vaccinia virus</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501257</gtr:grantReference><gtr:abstractText>VacV has been the most successful vaccine ever used, and its widespread application led to the eradication of smallpox from the world more than 25 years ago. Despite this, it is still needed today because of the fear of bioterrorism with variola virus, the virus that caused smallpox. In UK the vaccine has been used recently to vaccinate some healthcare workers against smallpox, so that if there were a case of smallpox sometime in the future, these workers could care for the patient(s) without contracting and spreading smallpox themselves. Some research programmes in UK, USA and elsewhere are trying to develop safer vaccines and new drugs for smallpox, that might be used in the future.

The research proposal aims to understand more about the genes of VacV, the smallpox vaccine, and to use this information to build safer vaccines for smallpox. In addition, because VacV can be modified to express genes derived from other microbes that cause disease, it can be used as a vaccine against those diseases too. Indeed it can be used against some cancers also. There is therefore a compelling need to understand more fully the VacV genes, how they work and how their manipulation can give rise to new vaccines that are safer and induce stronger immune responses in those vaccinated.

The applicant has communicated the results of his research and the purpose of this research to the public in several ways. Like all staff at Imperial College London, research findings are published in international scientific journals and are described at scientific conferences in UK and abroad. Unpublished research data are frequently used in teaching undergraduate students at Imperial College, other UK universities and research institutions overseas. In addition, the applicant has been interactive with national newspapers, TV and radio. As Chairman of the WHO committee on variola virus research, he is responsible for helping to shape policy for WHO. Similarly, he has done this within UK, by contributing to committees from the Royal Society, Academy of Medical Sciences, the Department of Health and Ministry of Defence. He contributes to policy on microbiology nationally by being a council member of the society for general microbiology, and internationally by being vice-president (and president-elect) of the virology division of the international union of microbiological societies (IUMS).</gtr:abstractText><gtr:technicalSummary>Vaccinia virus (VacV) is the live vaccine used to eradicate smallpox. It is a platform on which new vaccines for infectious disease and cancer can be built and an excellent model for studying the interaction of a mammalian virus with the host cell and immune system. This grant application proposes to study how vaccinia virus (VacV) interacts with the host cell and mammalian host and to apply this information to the development of improved poxvirus based vaccines for infectious disease and cancer. Three broad areas will be investigated. (1) VacV entry into and exit from cells, with emphasis on the extracellular enveloped virus (EEV) form. In particular, we will study the ligand-dependent and non-fusogenic dissolution of the EEV outer membrane, a process of membrane shedding that is unique in virology. (2) How VacV and subviral particles thereof move within infected cells after entry and during morphogenesis and exit. The movement of virus cores, intracellular mature virus (IMV) and intracellular enveloped virus (IEV) all require microtubules, but these virus particles each have different surface proteins and so must use different molecules to engage the microtubule motors. The virus proteins needed for these interactions will be sought and their mechanism of action studied. 3) VacV proteins that interfere with the host immune system will be studied and mutants lacking these genes will be constructed and tested for virulence and immunogenicity in vivo. Genes encoding proteins that are found to diminish virus immunogenicity will be deleted from vaccine strains of VacV such as modified virus Ankara (MVA) and the immunogenicity of those viruses tested. Finally, in collaboration with Professor D. Stuart in Oxford we will determine the structure of selected virus structural proteins and immunomodulators.</gtr:technicalSummary><gtr:fund><gtr:end>2010-11-25</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-11-26</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1400365</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nuffield Department of Clinical Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Structural Biology</gtr:department><gtr:description>structural and functional studies of vaccinia virus proteins</gtr:description><gtr:id>3FB996BE-A26E-4421-91FB-0DD712E1CAA4</gtr:id><gtr:impact>Pubmed 17485524, 17681535, 18208323, 18704168</gtr:impact><gtr:partnerContribution>Professor Stuart's lab determine the structure of vaccinia virus proteins and we undertake functional characterisation of the same vaccinia virus proteins.</gtr:partnerContribution><gtr:piContribution>Professor Stuart's lab determine the structure of vaccinia virus proteins and we undertake functional characterisation of the same vaccinia virus proteins.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Molecular Virology</gtr:department><gtr:description>Studies on herpes simplex virus morphogenesis</gtr:description><gtr:id>217EE89B-1027-4EBD-AC78-B04EA671D1BD</gtr:id><gtr:impact>229. Hollinshead, M., Johns, H.L., Sayers, C.L., Gonzalez-Lopez, C., Smith, G.L. &amp;amp; Elliott. G. (2012). Endocytic tubules regulated by Rab GTPases 5 and 11 are used for envelopment of herpes simplex virus. EMBO J. published online 18.9.2012 doi:10.1038/emboj.2012.262.</gtr:impact><gtr:partnerContribution>Cell biology of cells infected with herpes simplex virus</gtr:partnerContribution><gtr:piContribution>Microscopy of cells infected with herpes simplex virus</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Biological Sciences Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Functional studies on Golgi anti-apoptotic protein</gtr:description><gtr:id>F3C4039A-831E-462D-8FE1-5AF9CB54B329</gtr:id><gtr:impact>228. Carrara, G., Saraiva, N., Gubser, C., Johnson, B.F. &amp;amp; Smith, G.L. (2012). A six membrane topology for Golgi anti-apoptotic protein and Bax inhibitor-1 (BI-1) provides a model for the transmembrane bax inhibitor containing motif (TMBIM) family. J. Biol. Chem. 287, 15896-15905. 14.3.2012. doi:10.1074/jbc.M111.336149.</gtr:impact><gtr:partnerContribution>electrophysiology</gtr:partnerContribution><gtr:piContribution>Collaboration on the ion channel activity of the Golgi anti-apoptotic protein</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>school visit Hertfordshire</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EC4E005A-7421-481E-BAEC-209AC4B640EB</gtr:id><gtr:impact>100 pupils attended lecture and participated in question and answer session

applications for entry into Cambridge University were submitted</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>visit of school party to research labs</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>F3B94E99-5508-4507-B824-9A456398D1E4</gtr:id><gtr:impact>visit of school party to research labs, demonstations, lectures, visit to Royal Society (2007), visit to Wellcome Collection (2008), visit to Darwin exhibition at Science Museum (2009)

some of students applied to do medicine or science at imperial college london</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>school visit, Yorkshire</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>D9A2906F-457E-4DDF-84B8-B7C9BC04F616</gtr:id><gtr:impact>multiple visits to schools in Peterborough, York, Hertford, Ampleforth. Audiences from

Three schools visited our research labs, Science Museum, Wellcome Foundation, Royal Society and some pupils entered higher education in biology or medicine subsequently.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>school visit and lecture, Oxfordshire</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8EA2280A-FCDB-463B-B17F-5F19DFEA2A41</gtr:id><gtr:impact>100 biology students attended lecture and participated in question and answer session

future visits have been requested. school visit to research lab being scheduled</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme grant G1000207</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C7C2F193-CDA1-467B-917D-BF7F53DF296B</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member Royal Society Science Policy Advisory Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E4BD2E31-A3DA-4782-8FBC-287A98796BC0</gtr:id><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>President, International Union of Microbiological Societies</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B3CFB989-96D5-426D-BB94-616838E5A5DA</gtr:id><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chairman WHO advisory committee on variola virus research</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>493E0EC3-68D8-4320-A26E-308445F435B3</gtr:id><gtr:impact>advice on research using live variola virus</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chairman Royal Society Committee for Scientific Aspects of International Security</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>662D2156-368C-4E38-8686-BB6DDF27E579</gtr:id><gtr:impact>measures for biosecurity</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F58C9B7-CDD5-4A6F-B584-4CD183E79F89"><gtr:id>9F58C9B7-CDD5-4A6F-B584-4CD183E79F89</gtr:id><gtr:title>Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f8c102c038313fa2b866f90fd9fa2acf"><gtr:id>f8c102c038313fa2b866f90fd9fa2acf</gtr:id><gtr:otherNames>Graham SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7F975CF1-B304-4C8D-9218-37F7D7DAC1AB"><gtr:id>7F975CF1-B304-4C8D-9218-37F7D7DAC1AB</gtr:id><gtr:title>How vaccinia virus has evolved to subvert the host immune response.</gtr:title><gtr:parentPublicationTitle>Journal of structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9e5c2c2d3d6fea623305cf1e13fa45a9"><gtr:id>9e5c2c2d3d6fea623305cf1e13fa45a9</gtr:id><gtr:otherNames>Bahar MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1047-8477</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/630C5EFD-5914-4B42-A65A-2C2133EE8FE6"><gtr:id>630C5EFD-5914-4B42-A65A-2C2133EE8FE6</gtr:id><gtr:title>Vaccinia virus B5 protein affects the glycosylation, localization and stability of the A34 protein.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5a3bdbb61b6aeb4c95741c5d5d1dd6d5"><gtr:id>5a3bdbb61b6aeb4c95741c5d5d1dd6d5</gtr:id><gtr:otherNames>Breiman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BCC0A9DB-52D4-4D9F-A43D-490596A5947B"><gtr:id>BCC0A9DB-52D4-4D9F-A43D-490596A5947B</gtr:id><gtr:title>Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9f0cbd4141d0c658f1b3df550a603c3f"><gtr:id>9f0cbd4141d0c658f1b3df550a603c3f</gtr:id><gtr:otherNames>Fahy AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E7F6E29F-6FCD-4165-910E-50A4006BCAA3"><gtr:id>E7F6E29F-6FCD-4165-910E-50A4006BCAA3</gtr:id><gtr:title>Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kappaB activation.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f0143de37e46d8a91c66f83dee9425f2"><gtr:id>f0143de37e46d8a91c66f83dee9425f2</gtr:id><gtr:otherNames>McCoy LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/49DC7D15-835A-49AE-89E4-2BAC575A97C9"><gtr:id>49DC7D15-835A-49AE-89E4-2BAC575A97C9</gtr:id><gtr:title>Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2a2f1a9b626406cb0e59633f10d0c7c7"><gtr:id>2a2f1a9b626406cb0e59633f10d0c7c7</gtr:id><gtr:otherNames>Carter GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C4AD4824-B0C6-4897-9E24-297850AD0EA4"><gtr:id>C4AD4824-B0C6-4897-9E24-297850AD0EA4</gtr:id><gtr:title>Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8df59a06de261b40e57651a2df865631"><gtr:id>8df59a06de261b40e57651a2df865631</gtr:id><gtr:otherNames>Cooray S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/29BE09E7-02F4-4C27-823C-D7033E855E92"><gtr:id>29BE09E7-02F4-4C27-823C-D7033E855E92</gtr:id><gtr:title>Inhibition of IkappaB kinase by vaccinia virus virulence factor B14.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d8a2d4225dfaae1d8825f647a15dc0ec"><gtr:id>d8a2d4225dfaae1d8825f647a15dc0ec</gtr:id><gtr:otherNames>Chen RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A9B3ED10-E1D3-4C1D-B560-FDA249544A7A"><gtr:id>A9B3ED10-E1D3-4C1D-B560-FDA249544A7A</gtr:id><gtr:title>Vaccinia virus morphogenesis and dissemination.</gtr:title><gtr:parentPublicationTitle>Trends in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35c34ed729fbda00ed41955e94795c37"><gtr:id>35c34ed729fbda00ed41955e94795c37</gtr:id><gtr:otherNames>Roberts KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0966-842X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6887DA2A-A180-4230-9A56-C7BB0E1F121C"><gtr:id>6887DA2A-A180-4230-9A56-C7BB0E1F121C</gtr:id><gtr:title>Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8428373b18bd0a52b3e33311d03b3321"><gtr:id>8428373b18bd0a52b3e33311d03b3321</gtr:id><gtr:otherNames>Lee LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/748FEA5C-BCF6-4D99-BEEC-EE4FA6E42E67"><gtr:id>748FEA5C-BCF6-4D99-BEEC-EE4FA6E42E67</gtr:id><gtr:title>Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dee48c5143d44fce0d7ec65518844faf"><gtr:id>dee48c5143d44fce0d7ec65518844faf</gtr:id><gtr:otherNames>Jacobs N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/508B3736-F804-4B45-91E0-68CB0F862455"><gtr:id>508B3736-F804-4B45-91E0-68CB0F862455</gtr:id><gtr:title>Cowpox virus pneumonia in a domestic cat in Great Britain.</gtr:title><gtr:parentPublicationTitle>The Veterinary record</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3d0c6d7ecadf6a10cfe2ba6a0ee6e3df"><gtr:id>3d0c6d7ecadf6a10cfe2ba6a0ee6e3df</gtr:id><gtr:otherNames>Sch?niger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0042-4900</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/82818307-6669-4E74-8849-433A6A1560D1"><gtr:id>82818307-6669-4E74-8849-433A6A1560D1</gtr:id><gtr:title>Acidic residues in the membrane-proximal stalk region of vaccinia virus protein B5 are required for glycosaminoglycan-mediated disruption of the extracellular enveloped virus outer membrane.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35c34ed729fbda00ed41955e94795c37"><gtr:id>35c34ed729fbda00ed41955e94795c37</gtr:id><gtr:otherNames>Roberts KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C4F61A92-0460-4CC3-A8D5-718C02991652"><gtr:id>C4F61A92-0460-4CC3-A8D5-718C02991652</gtr:id><gtr:title>Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/27d3cd85143034c1c567ba303b3f3b13"><gtr:id>27d3cd85143034c1c567ba303b3f3b13</gtr:id><gtr:otherNames>Trilling M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/173D99F8-245A-4F08-99DA-42BCE5B13E39"><gtr:id>173D99F8-245A-4F08-99DA-42BCE5B13E39</gtr:id><gtr:title>Ligand-induced and nonfusogenic dissolution of a viral membrane.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bdfb66698bf12de7c9639a895d0cb7e8"><gtr:id>bdfb66698bf12de7c9639a895d0cb7e8</gtr:id><gtr:otherNames>Law M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/88583332-00B0-4D2C-891D-72D1DB27819C"><gtr:id>88583332-00B0-4D2C-891D-72D1DB27819C</gtr:id><gtr:title>Intradermal immune response after infection with Vaccinia virus.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dee48c5143d44fce0d7ec65518844faf"><gtr:id>dee48c5143d44fce0d7ec65518844faf</gtr:id><gtr:otherNames>Jacobs N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99FBEA97-C22E-4A14-9C5F-D3C663F8066A"><gtr:id>99FBEA97-C22E-4A14-9C5F-D3C663F8066A</gtr:id><gtr:title>Vaccinia virus intracellular enveloped virions move to the cell periphery on microtubules in the absence of the A36R protein.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eda4fabbae7507f1928eaae5f776bb1d"><gtr:id>eda4fabbae7507f1928eaae5f776bb1d</gtr:id><gtr:otherNames>Herrero-Mart?nez E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1DA649E8-657C-41BF-9E0B-D437672D40A9"><gtr:id>1DA649E8-657C-41BF-9E0B-D437672D40A9</gtr:id><gtr:title>Protein B5 is required on extracellular enveloped vaccinia virus for repulsion of superinfecting virions.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/473225cdacfdb90e6e956a114be45abd"><gtr:id>473225cdacfdb90e6e956a114be45abd</gtr:id><gtr:otherNames>Doceul V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E7AF6921-D481-413B-BAD7-201A7A733D35"><gtr:id>E7AF6921-D481-413B-BAD7-201A7A733D35</gtr:id><gtr:title>Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/821ff415d151531cce0650bc75118f28"><gtr:id>821ff415d151531cce0650bc75118f28</gtr:id><gtr:otherNames>P?tz MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/15F9EC95-C841-418B-8A4B-946969A4B816"><gtr:id>15F9EC95-C841-418B-8A4B-946969A4B816</gtr:id><gtr:title>Vaccinia protein F12 has structural similarity to kinesin light chain and contains a motor binding motif required for virion export.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e0adf384fa0613a7938653295b71e04"><gtr:id>8e0adf384fa0613a7938653295b71e04</gtr:id><gtr:otherNames>Morgan GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E0C62A51-0A5A-4807-A9A0-1402D3C428E7"><gtr:id>E0C62A51-0A5A-4807-A9A0-1402D3C428E7</gtr:id><gtr:title>Genome sequence diversity and clues to the evolution of variola (smallpox) virus.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/28a5648fd7162603c085aad4d7d908ca"><gtr:id>28a5648fd7162603c085aad4d7d908ca</gtr:id><gtr:otherNames>Esposito JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/508D3B0C-5A69-40D5-B5DA-3C0C9298008A"><gtr:id>508D3B0C-5A69-40D5-B5DA-3C0C9298008A</gtr:id><gtr:title>Yaba-like disease virus chemokine receptor 7L, a CCR8 orthologue.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3dcf0a461efba2faa69a896a1494af53"><gtr:id>3dcf0a461efba2faa69a896a1494af53</gtr:id><gtr:otherNames>Najarro P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1BB6E5FE-EEBC-476E-968D-EC2D59384378"><gtr:id>1BB6E5FE-EEBC-476E-968D-EC2D59384378</gtr:id><gtr:title>Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/03e468d947d313423e727868bef5242d"><gtr:id>03e468d947d313423e727868bef5242d</gtr:id><gtr:otherNames>Clark RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1BB59F89-A691-4215-B3C1-9A78972691D4"><gtr:id>1BB59F89-A691-4215-B3C1-9A78972691D4</gtr:id><gtr:title>Repulsion of superinfecting virions: a mechanism for rapid virus spread.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/473225cdacfdb90e6e956a114be45abd"><gtr:id>473225cdacfdb90e6e956a114be45abd</gtr:id><gtr:otherNames>Doceul V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/758C9016-AA8F-412E-B9AC-87FA3255BC5E"><gtr:id>758C9016-AA8F-412E-B9AC-87FA3255BC5E</gtr:id><gtr:title>[Rapid cell-to-cell spread: a story of jumping viruses].</gtr:title><gtr:parentPublicationTitle>Medecine sciences : M/S</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/473225cdacfdb90e6e956a114be45abd"><gtr:id>473225cdacfdb90e6e956a114be45abd</gtr:id><gtr:otherNames>Doceul V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0767-0974</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8DE13C91-9291-4750-85F9-3EE0D743E83D"><gtr:id>8DE13C91-9291-4750-85F9-3EE0D743E83D</gtr:id><gtr:title>Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/887d8d0668071124a9629e98422c5b0c"><gtr:id>887d8d0668071124a9629e98422c5b0c</gtr:id><gtr:otherNames>Huang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/448DEE07-89A7-4938-AF49-CA9F08B3862A"><gtr:id>448DEE07-89A7-4938-AF49-CA9F08B3862A</gtr:id><gtr:title>Vaccinia virus intracellular enveloped virions move to the cell periphery on microtubules in the absence of the A36R protein.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eda4fabbae7507f1928eaae5f776bb1d"><gtr:id>eda4fabbae7507f1928eaae5f776bb1d</gtr:id><gtr:otherNames>Herrero-Mart?nez E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/765C7CB1-F7EF-4CA8-BDEC-9197C51A8BD1"><gtr:id>765C7CB1-F7EF-4CA8-BDEC-9197C51A8BD1</gtr:id><gtr:title>Cowpox virus pneumonia in a domestic cat in Great Britain.</gtr:title><gtr:parentPublicationTitle>The Veterinary record</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3d0c6d7ecadf6a10cfe2ba6a0ee6e3df"><gtr:id>3d0c6d7ecadf6a10cfe2ba6a0ee6e3df</gtr:id><gtr:otherNames>Sch?niger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0042-4900</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6553D743-61E4-4C15-BA6C-6AB319270EC8"><gtr:id>6553D743-61E4-4C15-BA6C-6AB319270EC8</gtr:id><gtr:title>Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d8a2d4225dfaae1d8825f647a15dc0ec"><gtr:id>d8a2d4225dfaae1d8825f647a15dc0ec</gtr:id><gtr:otherNames>Chen RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501257</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>